Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MDxHealthMDXH -4.11%40 EV-to-EBIT is -4.37 as of Aug. 12, 2026. GuruFocus rates MDXH with a GF Score™ of 40/100 and a GF Value™ of $2.18 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, MDxHealth ranks worse than 952380% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
MDxHealth's Enterprise Value for the quarter that ended in Mar. 2026 was $180.9 Mil.
MDxHealth's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDxHealth EV-to-EBIT Related Terms
MDxHealth EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for MDxHealth's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, MDxHealth's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MDxHealth EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where MDxHealth's EV-to-EBIT falls into.
MDxHealth's current Enterprise Value is $85.4 Mil.
MDxHealth's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDxHealth (MDXH) has a EV-to-EBIT of -4.37 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MDxHealth and its competitors. According to the industry distribution chart, MDxHealth ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry.
Is MDxHealth's EV-to-EBIT too high?
MDxHealth's current EV-to-EBIT is -4.37. Based on the distribution chart, MDxHealth ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, MDxHealth has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's EV-to-EBIT compare to AWHL and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, MDxHealth ranks #999999 out of 105 companies for EV-to-EBIT. This places MDxHealth in the lower half of its industry. The industry median EV-to-EBIT is 23.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.79, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MDxHealth and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MDxHealth's current EV-to-EBIT is -4.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (MDXH) is currently considered Possible Value Trap. The stock's GF Value™ is $2.18, compared to a current price of $0.44 — trading 79.8% below its estimated fair value. The current EV-to-EBIT is -4.37. MDxHealth's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For MDxHealth (MDXH), the current EV-to-EBIT is -4.37 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MDxHealth (MDXH) Overvalued in 2026?
Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued.
The current stock price of $0.44 is trading 79.8% below its estimated GF Value™ of $2.18.
GuruFocus considers MDxHealth to be Possible Value Trap.
Key valuation signals for MDXH:
EV-to-EBIT: -4.37
GF Value™: $2.18 vs. price of $0.44 (79.8% below fair value)
No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
40GF Score
Get the complete analysis for MDXH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXH has been successfully added to your 
